The maturation of the CAR-T therapy field may be cause for re-evaluation of some of the early postmarketing regulatory requirements for the cell-based gene therapies.
Long-term follow-up obligations could be reduced, and the existing Risk Evaluation and Mitigation Strategy for the class could be eliminated, given the real-world experience with the products to date, experts said
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?